Phio Pharmaceuticals Corp. logo

Phio Pharmaceuticals Corp.

PHIO | NASDAQ
Chart Builder DCF Calculator
$1.01
-$0.02 (-1.94%)
At close: Sep 21, 2026, 4:00 PM ET
$1.06
+$0.05 (+4.95%)
Pre-market: Sep 22, 2026, 6:21 AM ET
TTM
Period Ending
Q2 2026
Jun 29, 2026
Q1 2026
Mar 30, 2026
Q4 2025
Dec 30, 2025
Q3 2025
Sep 29, 2025
Q2 2025
Jun 29, 2025
Q1 2025
Mar 30, 2025
Q4 2024
Dec 30, 2024
Q3 2024
Sep 29, 2024
Q2 2024
Jun 29, 2024
Q1 2024
Mar 30, 2024
Q4 2023
Dec 30, 2023
Q3 2023
Sep 29, 2023
Q2 2023
Jun 29, 2023
Q1 2023
Mar 30, 2023
Q4 2022
Dec 30, 2022
Q3 2022
Sep 29, 2022
Q2 2022
Jun 29, 2022
Q1 2022
Mar 30, 2022
Q4 2021
Dec 30, 2021
Q3 2021
Sep 29, 2021
Q2 2021
Jun 29, 2021
Q1 2021
Mar 30, 2021
Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
2.66M 3.73M 3.75M 3.26M 2.72M 2.51M 3.64M 2.7M 3.87M 3.05M 4.03M 5.61M 6.31M 7.56M 7.01M 7.62M 7.79M 6.48M 7.33M 5.15M 3.73M 4.51M
Gross Profit
-2.66M -3.73M -3.75M -3.26M -2.72M -2.51M -3.64M -2.7M -3.87M -3.05M -4.03M -5.61M -6.31M -7.56M -7.01M -7.62M -7.79M -6.48M -7.33M -5.15M -3.73M -4.51M
Operating Income
-9.21M -11.52M -9.22M -8.36M -7.45M -7.05M -7.39M -7.49M -8.67M -9.31M -10.7M -11.66M -12.45M -12.42M -11.46M -12.18M -12.35M -12.51M -13.51M -12.52M -11.09M -10.08M
Interest Income
161K 280K 244K 475K 475K 356K 231K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-12.9M -10.93M -8.7M -7.95M -7.09M -6.77M -7.15M -7.42M -8.68M -9.38M -10.83M -11.66M -12.46M -12.44M -11.48M -12.2M -12.37M -12.52M -13.29M -12.3M -10.87M -9.85M
Net Income
-12.9M -10.93M -8.7M -7.95M -7.09M -6.77M -7.15M -7.42M -8.68M -9.38M -10.83M -11.66M -12.46M -12.44M -11.48M -12.2M -12.37M -12.52M -13.29M -12.3M -10.87M -9.85M
Selling & General & Admin
4.94M 4.99M 4.6M 4.23M 3.86M 3.67M 3.74M 3.78M 3.8M 3.92M 4.32M 4.72M 4.81M 4.86M 4.45M 4.56M 4.56M 4.47M 4.63M 4.64M 4.62M 4.39M
Research & Development
8.53M 6.53M 4.62M 4.13M 3.59M 3.38M 3.64M 3.66M 4.83M 5.35M 6.33M 6.94M 7.64M 7.56M 7.01M 7.62M 7.79M 8.04M 8.89M 7.84M 6.42M 5.64M
Other Expenses
-2.66M -3.73M -3.75M -3.26M -2.72M -2.51M -3.64M -2.66M -3.82M -3.01M -3.99M -5.61M -6.31M -7.56M -7.01M -7.62M -7.79M -6.48M -7.33M -5.1M -3.69M -4.46M
Operating Expenses
10.82M 7.78M 5.47M 5.11M 4.73M 4.54M 3.74M 4.79M 4.81M 6.26M 6.66M 6.05M 6.15M 4.86M 4.45M 4.56M 4.56M 6.03M 6.18M 7.38M 7.36M 5.57M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 5K 15K 17K 18K 16K 9K 9K 8K 8K 8K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
9.21M 11.52M 9.22M 8.36M 7.45M 7.05M 7.39M 7.49M 8.67M 9.31M 10.7M 11.66M 12.45M 12.42M 11.46M 12.18M 12.35M 12.51M 13.51M 12.52M 11.09M 10.08M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Shares Outstanding (Basic)
11.62M 11.62M 11.62M 5.47M 4.79M 4.31M 787.47K 990.03K 510.19K 508.39K 415.95K 270.86K 191.86K 126.79K 126.43K 126.38K 126.34K 125.47K 125.19K 125.19K 125.19K 98.79K
Shares Outstanding (Diluted)
11.62M 11.62M 11.62M 5.47M 4.79M 4.31M 787.47K 990.03K 510.19K 508.39K 415.95K 270.86K 191.86K 126.79K 126.43K 126.38K 126.34K 125.47K 125.19K 125.19K 125.19K 98.79K
EPS (Basic)
-1.34 -1.43 -41.07K -41.07K -41.07K -41.08K -9.77 -13.96 -22.68 -32.35 -56.52 -72.48 -90.55 -97.37 -90.03 -97.08 -98.64 -99.99 -113.41 -131.89 -145.18 -160.12
EPS (Diluted)
-1.34 -1.43 -41.07K -41.07K -41.07K -41.08K -9.77 -13.96 -22.68 -32.35 -56.52 -72.48 -90.55 -97.37 -90.03 -97.08 -98.64 -99.99 -113.41 -131.89 -145.18 -160.12
EBITDA
-8.76M -10.93M -8.69M -7.91M -7.04M -6.72M -7.07M -7.34M -8.58M -9.27M -10.74M -11.6M -12.39M -12.36M -11.39M -12.11M -12.27M -12.43M -13.44M -12.42M -10.99M -9.98M
EBIT
-8.77M -10.93M -8.7M -7.95M -7.09M -6.77M -7.15M -7.42M -8.68M -9.38M -10.83M -11.66M -12.45M -12.43M -11.46M -12.18M -12.35M -12.51M -13.51M -12.52M -11.09M -10.08M
Depreciation & Amortization
4K 4.5K 3.5K 44.5K 42.5K 43K 77K 78K 93K 107K 89K 61K 61K 65K 71K 76K 80K 79K 75K 100K 99K 100K

© 2026 bestshares.com. All rights reserved.